Visionflex Group Limited (ASX:VFX), an Australian telehealth and remote diagnostic technology company, released its Appendix 4E Preliminary Final Report for the year ended 30 June 2026. The company reported a net loss of $54,772 for FY26, an improvement of 98% on the prior year loss of $3,093,317. Revenues from ordinary activities (continuing operations) were $4,184,558, down 10% from the prior year. The result marks a significant inflection toward near-breakeven following the cost reset measures implemented during the year.

About Visionflex Group

Visionflex Group Limited (ASX:VFX, ABN 25 138 897 533) is a clinical virtual care technology company that provides healthcare, telehealth, and remote diagnostic solutions to local and international markets. The company's product suite includes the ProEX clinical virtual care software platform, the Vision Telehealth Platform, VF Sync, and a range of peripheral medical devices including high-definition clinical cameras and digital stethoscopes. Visionflex serves aged care, rural and remote health, indigenous healthcare, general practice, the oil and gas sector, merchant navy, armed forces, and correctional facilities. The company was formerly known as 1st Group Limited and changed its name in November 2023.

FY26 Results — Appendix 4E Filed 2026

Visionflex Group's FY26 Appendix 4E reported revenues from ordinary activities (continuing operations) of $4,184,558, a 10% decline on the prior year. For continuing and discontinued operations combined, revenues were also $4,184,558. The loss from ordinary activities after tax (continuing operations) was $57,805, compared with the prior year loss of $3,093,317 — a 98% improvement marked as a "favourable movement" in the Appendix 4E. Including discontinued operations, the net loss for the year attributable to the owners of Visionflex Group Limited was $54,772.

Net tangible assets per ordinary security improved materially to negative 0.03 cents for the current reporting period, compared with negative 2.68 cents in the prior period. The prior period comparative information was restated to reflect the 50-for-1 share consolidation completed during FY26. No dividends were paid, recommended, or declared during the current financial period, consistent with the prior year.

Earlier in FY26, the company disclosed a February 2026 cost reset that materially reduced the operating cash outflow. During the third quarter of FY26 (January–March 2026), Revenue of $1.0 million was up 24% on the prior corresponding period, and Annual Recurring Revenue reached $1.99 million at the end of Q3 FY26, up 20% on the prior corresponding period.

Industry Context

The Australian telehealth sector has undergone a period of normalisation following the elevated adoption seen during the COVID-19 pandemic. Demand for clinical-grade telehealth technology — as distinct from consumer-facing video consultation platforms — has grown in areas such as aged care, rural health, and specialist outreach services, which are the core use cases for Visionflex's ProEX platform. The company's transition toward a higher proportion of recurring subscription revenue (approximately 55% of Q3 FY26 revenue was recurring) is consistent with a shift toward more predictable income streams in the sector.

Risks and Uncertainties

Visionflex Group's revenue declined 10% in FY26 and its net tangible assets per share remain in negative territory, reflecting an accumulated Deficit from prior years. While the near-breakeven result is an improvement, the company needs to demonstrate sustained revenue growth alongside cost discipline to achieve consistent profitability. The telehealth market is competitive, and the company's relatively small scale means it faces execution risk as it tries to grow recurring revenues and expand its clinical platform internationally. The company's cash position and access to its existing Debt Facility with cornerstone investor Adcock Private Equity were noted as key Liquidity supports during the year.